UPDATES IN MEDICINE

2021-12-31 16:24:30 ​​ Dolutegravir in Children with HIV-1 Infection

In an open-label, randomized, noninferiority trial, dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents starting first- or second-line therapy for HIV type 1 infection. Dolutegravir-based ART was superior to standard-care ART.


Join @Updates_in_Medicine Open / Comment

2021-12-25 16:00:08 ​​ Covid-19 Vaccine Booster Effects across Age Groups

In a study involving 4.7 million fully vaccinated persons in Israel, the rate of confirmed Covid-19 was lower among those who received a booster than among those who did not by a factor of approximately 10. Among participants 60 years of age or older, the rate of severe illness was lower by a factor of 17.9 and the rate of death by a factor of 14.7.


Join @Updates_in_Medicine Open / Comment

2021-12-24 06:30:58 ​​ Remdesivir for Prevention of Covid-19 Progression

Among nonhospitalized patients with Covid-19–related symptoms that began less than a week previously, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. Adverse effects in the remdesivir group were similar to those in the placebo group.


Join @Updates_in_Medicine Open / Comment

2021-12-18 08:35:21 ​​ FIRST ORAL TABLET FOR COVID

Molnupiravir for Oral Treatment of Covid-19 in Non hospitalized Patients (MOVe-OUT)

Early treatment with molnupiravir (oral, small-molecule antiviral prodrug that is active against SARS-CoV-2.) reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.


Join @Updates_in_Medicine Open / Comment

2021-12-17 08:31:03 ​​ A Nobel Prize for Sensational Research


@Updates_in_Medicine Open / Comment

2021-12-13 04:20:49 ​​ 2021 ACR / VF Guidelines for the Management of ANCA –Associated Vasculitis


Join @Updates_in_Medicine Open / Comment

2021-12-09 07:56:39 ​​ Effect of Booster on Mortality Due to Covid-19 in Israel

Among 843,208 participants in Israel who were 50 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster. The study period was 54 days; adverse effects were not recorded.


Join @Updates_in_Medicine Open / Comment

2021-12-08 07:47:01 ​​ Mixing Pfizer, AstraZ COVID-19 shots with Moderna gives better immune response -UK study

Methods
Previously immunised people with a single dose of AstraZeneca or Pfizer in the community, were randomly assigned to receive a second dose intramuscularly (8–12 weeks after the first dose) with the homologous vaccine, Moderna or Novavax.


Interpretation
Heterologous second dosing with Moderna, but not Novavax, increased transient systemic reactogenicity compared with homologous schedules. Multiple vaccines are appropriate to complete primary immunisation following priming with Pfizer or AstraZeneca, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification


Join @Updates_in_Medicine Open / Comment

2021-12-02 14:46:26 ​​ Myocarditis after Covid-19 mRNA Vaccine

1. Myocarditis after Covid-19 Vaccination in a Large Health Care Organisation in Israel
G. Witberg and Others

Among 2.5 million patients who received the BNT162b2 ( pfizer ) mRNA vaccine in a large Israeli health care system, the incidence of myocarditis at 42 days was 2.13 cases per 100,000 persons, with the highest incidence (10.69 per 100,000 persons) among male patients between the ages of 16 and 29 years. Most cases of myocarditis were mild or moderate.

__________________________________

2. Myocarditis after BNT162b2 ( Pfizer) Vaccine in Israel
D. Mevorach and Others

In an Israeli Ministry of Health database, 136 definite or probable cases of myocarditis were detected among 5 million vaccinated persons. The rate ratio after two doses as compared with unvaccinated persons was 2.35, with the highest risk among male recipients between the ages of 16 and 19 years.


Join @Updates_in_Medicine Open / Comment

2021-12-01 06:20:00 ​​ Anthony Fauci : Omicron 'Very Different From Other Variants'

An abundance of mutations make the new variant very unpredictable, but booster shots may still offer effective "cross-protection," Fauci said.


@Updates_in_Medicine Open / Comment